(1) Background: Pelvic osteosarcoma accounts for a small proportion of osteosarcoma cases but is associated with significantly poorer outcomes than extremity tumors. This study evaluates contemporary survival outcomes and prognostic factors in a single-center cohort. (2) Methods: We retrospectively analyzed 56 patients with primary pelvic osteosarcoma treated between 2006 and 2019. Demographic characteristics, surgical margins, adjuvant therapies, local recurrence, metastasis, survival outcomes and the Musculoskeletal Tumor Society (MSTS) Score were assessed. Kaplan–Meier analysis was performed for overall survival (OS), including subgroup analyses by age and Enneking classification. (3) Results: Median age at surgery was 24 years. R0 margins were achieved in 96.4% of cases. OS at 1, 3, and 5 years was 69%, 54%, and 48%, respectively. Younger patients (≤25 years) showed significantly improved 5-year OS (68%) compared with older groups. Enneking classification showed limited prognostic discrimination. Metastatic disease at any time strongly predicted inferior survival (5-year OS 30% vs. 66%). The mean MSTS score one year after operation was 14.1 points. Functional outcome showed marked variability and was strongly influenced by patient age, extent of resection, reconstruction strategy, and postoperative complications. Younger patients and those undergoing limited or non-acetabular reconstructions achieved superior functional results, whereas complex endoprosthetic reconstructions and revision-requiring complications were associated with reduced MSTS scores. (4) Conclusions: Pelvic osteosarcoma continues to be associated with substantial morbidity and mortality. Younger age and absence of metastatic disease are strong predictors of improved survival. Functional outcomes are typically moderate; further advances are needed to improve results.
(1) Background: Megaprosthetic reconstruction of the knee is frequently required in limb salvage surgery for oncologic indications and in complex revision arthroplasty. The Modular Universal Tumor and Revision System (MUTARS) Total Knee prosthesis is widely used in these situations. The aim of this study was to evaluate revision-free implant survival following MUTARS Total Knee implantation and to compare outcomes between primary implantation and use as a conversion procedure after failure of a previous knee prosthesis. (2) Methods: A retrospective cohort study was performed including 36 patients who underwent MUTARS Total Knee implantation at a single institution. Patients were stratified into primary implantation (n = 24) and conversion after failed prosthesis (n = 12). The primary endpoint was time to first revision. (3) Results: Overall revision-free survival was 51.6% at 2 years and 29.3% at 5 years. No significant difference in revision-free survival was observed between primary implantation and conversion procedures (log-rank p = 0.67). When mechanical failure (Henderson type III) was considered as the sole endpoint, implant survival was substantially higher, with 88.3% survival at 2 years and 57.2% at 5 years. Infection-related implant survival was 72.0% at both 2 and 5 years. Secondary amputation was required in 7 of 36 patients (19.4%), with a higher proportion observed in the primary implantation group (25.0% vs. 8.3%). Most amputations occurred within the early postoperative period. (4) Conclusions: MUTARS Total Knee implantation is associated with a substantial revision burden; however, conversion after failed prosthesis did not result in inferior revision-free survival compared with primary implantation. Endpoint-specific analyses demonstrate that biological complications, particularly infection, represent the dominant drivers of early failure.